Evidence map›Paper›PMID 27818713›Full record

ArticleCellular and molecular bioengineering2016

Mechanism of Enhanced Cellular Uptake and Cytosolic Retention of MK2 Inhibitory Peptide Nano-polyplexes.

Kameron V Kilchrist, Brian C Evans, Colleen M Brophy, Craig L Duvall

Abstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. HOPS-dependent endosomal fusion required for efficient cytosolic delivery of therapeutic peptides and small proteins.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  17. Intranasal MMI-0100 Attenuates AβFrontiers in immunology · 2019
    Article
  18. Article
  19. Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Kameron V KilchristDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Brian C EvansDivision of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Colleen M BrophyDivision of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Veterans Affairs Medical Center, VA Tennessee Valley Healthcare System, Nashville TN 37212, USA.
Craig L DuvallDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Vanderbilt University · USVanderbilt University Medical Center · USVA Tennessee Valley Healthcare System · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft PatencyR01HL122347 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2016 to 2020
$2.2M
Smart Polymer Based MK2 Inhibitor to Suppress Vascular Graft Intimal HyperplasiaR21HL110056 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2011 to 2012
$403k
NCI NIH HHS P30 CA068485NEI NIH HHS P30 EY008126NHLBI NIH HHS R01 HL122347NHLBI NIH HHS R21 HL110056NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637
6 · The paper itself

Abstract

Electrostatic complexation of a cationic MAPKAP kinase 2 inhibitory (MK2i) peptide with the anionic, pH-responsive polymer poly(propylacrylic acid) (PPAA) yields MK2i nano-polyplexes (MK2i-NPs) that significantly increase peptide uptake and intracellular retention. This study focused on elucidating the mechanism of MK2i-NP cellular uptake and intracellular trafficking in vascular smooth muscle cells. Small molecule inhibition of various endocytic pathways showed that MK2i-NP cellular uptake involves both macropinocytosis and clathrin mediated endocytosis, whereas the free peptide exclusively utilizes clathrin mediated endocytosis for cell entry. Scanning electron microscopy studies revealed that MK2i-NPs, but not free MK2i peptide, induce cellular membrane ruffling consistent with macropinocytosis. TEM confirmed that MK2i-NPs induce macropinosome formation and achieve MK2i endo-lysosomal escape and cytosolic delivery. Finally, a novel technique based on recruitment of Galectin-8-YFP was utilized to demonstrate that MK2i-NPs cause endosomal disruption within 30 minutes of uptake. These new insights on the relationship between NP physicochemical properties and cellular uptake and trafficking can potentially be applied to further optimize the MK2i-NP system and more broadly toward the rational engineering of nano-scale constructs for the intracellular delivery of biologic drugs.

Indexed as

Drug deliveryendosome escapemacropinocytosisnanoparticlepH-responsive polymervascular therapeutic

Identifiers

PMID27818713
PMCPMC5089375
OpenAlexW2412326609

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.